Archives
-
Anlotinib and VEGFR2-Driven Tumor Angiogenesis
2026-09-03
The reference study established anlotinib as a highly potent, orally active VEGFR2 inhibitor that suppresses tumor angiogenesis across biochemical, endothelial, ex vivo, and xenograft models. Its strongest preclinical effect arose from vascular disruption rather than direct tumor-cell cytotoxicity, providing a useful framework for mechanistic cancer research and anti-angiogenic assay design.
-
Marein Inhibits ABCG2 to Restore Chemosensitivity
2026-09-03
The 2024 Biochemical Pharmacology study identifies marein, a flavonoid from Coreopsis tinctoria Nutt, as a competitive inhibitor of the ABCG2 drug efflux transporter. Functional, cellular, analytical, and target-engagement experiments link marein activity to increased intracellular chemotherapy exposure and restored sensitivity in ABCG2-expressing resistant cancer cells.
-
Taltirelin Acetate: From Receptor to Assay
2026-09-02
Taltirelin acetate is more than a long-acting TRH analog: it is a tool for dissecting receptor-driven dopamine phenotypes. This assay-focused guide connects TRHR–RARα signaling with model selection, orthogonal readouts, and translational research design.
-
Lithium, Rab11a, and Exosomal Wnt10a in Bone Repair
2026-09-02
Chen and colleagues show that lithium enhances bone mesenchymal stem cell osteogenesis by increasing Rab11a-dependent secretion of exosomal Wnt10a and activating β-catenin signaling. The work connects intracellular vesicle trafficking with engineered exosome therapy and demonstrates that lithium-conditioned exosomes incorporated into GelMA hydrogels can improve bone regeneration in vivo.
-
Toremifene Citrate: SERM Research Guide
2026-09-01
Toremifene Citrate is an oral selective estrogen receptor modulator used to investigate estrogen receptor signaling and breast cancer biology. Product data define receptor-binding potency, assay concentration ranges, rodent dosing benchmarks, and handling requirements, while a Cochrane review provides clinical context against tamoxifen.
-
Primidone: TRPM3 and RIPK1 Research Guide
2026-09-01
Primidone, also known as Mysoline, combines established antiepileptic use with experimentally reported TRPM3, RIPK1, and hPON1 inhibition. Its research value depends on separating micromolar cellular assays from millimolar enzyme assays and on preserving route-specific dosing and solvent controls.
-
gamma-Glu-Cys (γ-Glu-Cys): Technical Guide
2026-08-31
gamma-Glu-Cys (γ-Glu-Cys) provides a defined L-glutathione biosynthesis intermediate for glutathione synthetase enzyme assay development, glutathione metabolism research, and selected plant or peptide workflows. This guide covers preparation, storage, controls, and troubleshooting while clarifying that the compound is for research use only and that long-term solution stability or biological outcomes should not be assumed.
-
METTL17, Mitochondrial Translation, and CRC Ferroptosis
2026-08-31
The reference study identifies METTL17 as a mitochondrial regulator that links RNA methylation and mitochondrial translation with ferroptosis resistance and colorectal cancer progression. Its combined cellular, molecular, and animal evidence suggests that disrupting METTL17 may expose a therapeutically actionable vulnerability, while also defining important limits for translating the findings beyond colorectal cancer models.
-
EdU, S-Phase Biology, and Translational Proof
2026-08-30
A mechanistic framework for using EdU flow cytometry to connect epithelial cell-cycle biology with translational decisions in diabetic foot ulcers, cancer research, genotoxicity, and pharmacodynamic studies.
-
p-Cresyl Sulfate: From Uremia to Valve Biology
2026-08-29
A mechanistic and translational perspective on how p-cresyl sulfate connects CKD-associated toxin retention with endothelial dysfunction, vascular calcification, and aortic valve biology.
-
Omeprazole A2845: Practical Research Workflow
2026-08-28
Omeprazole (SKU A2845) provides a defined H+,K+-ATPase inhibitor for controlled gastric acid secretion research, antiulcer activity studies, and related assay development. This guide focuses on dossier-supported identity, potency, solubility, storage, and workflow controls; the material is for scientific research only and is not intended for diagnostic, clinical, or therapeutic use.
-
How Cell Division Refines Drosophila Tissue Boundaries
2026-08-28
A 2026 Development study combines mathematical modelling, laser ablation, and live cell tracking to show that ectodermal divisions have a dual effect on the mesectoderm–ectoderm boundary. Divisions can challenge boundary integrity when actomyosin tension is lost, yet under normal conditions they also reduce junctional tension and increase ectodermal motility, sharpening the interface through tissue fluidity.
-
Serine/Glycine Restriction, PD-L1 Lactylation, and CRC
2026-08-27
A 2024 Cell Metabolism study shows that a serine/glycine-free diet can suppress colorectal cancer growth and increase cytotoxic T-cell accumulation, while also promoting immune evasion through PD-L1 lactylation. Its preclinical findings and early phase I clinical feasibility data support further evaluation of dietary metabolic intervention in combination with immune checkpoint blockade.
-
3-Bromopyruvate Reverses Cetuximab Resistance
2026-08-27
The reference study shows that combining 3-bromopyruvate with cetuximab can suppress colorectal cancer cells that are intrinsically or adaptively resistant to cetuximab. Its mechanistic contribution is the connection of FOXO3a restoration with AMPKα–Beclin1 signaling, PUMA activation, autophagy-dependent ferroptosis, and apoptosis.
-
Pepstatin A: A Causal Tool for Cathepsin D
2026-08-26
Pepstatin A is an aspartic protease inhibitor that can do more than suppress enzyme activity: it can test whether cathepsin D is causally involved in endothelial ischemia/reperfusion injury. This article translates recent autophagy-lysosomal findings into practical assay design, controls, and interpretation strategies.